Business Wire

Epassi Announces Leadership Transition

26.11.2025 11:00:00 CET | Business Wire | Press Release

Share

Epassi Group, a European leader in digital employee benefits technology, today announced that Nickyl Raithatha will join as Chief Executive Officer. Nickyl will assume the role in 2026. Pekka Rantala, who has served as CEO since September 2019, will remain on the Board as Non-Executive Chair.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126015983/en/

Pekka Rantala and Nickyl Raithatha

Over the past six years, Epassi Group has evolved from a Nordic success story into one of Europe’s leading SaaS employee benefits and wellbeing platforms. The company has expanded both its geographic footprint as well as its product portfolio, driven by a powerful combination of strong organic growth and strategic acquisitions, with backing from TA Associates and Warburg Pincus. Today it has a presence in ten countries and a team of 1,000 people. With net revenue expected to exceed €200 million in 2025, Epassi is redefining employee engagement across Europe – combining SaaS technology and expertise with a comprehensive, one-stop portfolio of benefits and wellbeing solutions designed to support happier, healthier workplaces.

Nickyl Raithatha is an experienced technology leader with a strong track record of building and scaling digital-first businesses that harness powerful network effects across B2C, B2B, and marketplace ecosystems. He is currently serving as Chief Executive Officer of Moonpig Group, where he has overseen a period of substantial growth and expansion into new markets. During his tenure, the company quadrupled revenues to £350 million and increased EBITDA fivefold to £97 million, while extending its footprint from a UK-focused business to a global operation across five countries through both organic growth and strategic acquisitions. He also led the company’s successful £1.4 billion IPO on the London Stock Exchange and developed the talent and technology platform required to scale the business effectively.

Pekka Rantala, outgoing CEO of Epassi, said, “When I joined Epassi in 2019, we were a team of 68 people with €8 million in revenue, operating in Finland and Sweden. Today, we serve customers in ten European countries, with 67% of our revenue generated outside the Nordics, and have expanded our product portfolio. After more than six incredibly rewarding years, I’ve decided to transition from full-time operational roles and focus on non-operational and board activities. I am very excited and committed to continue serving Epassi from the Board.”

“It has been a true privilege to lead Epassi and to work alongside such a talented and committed team of Epassians,” he continued. “Together we’ve built a strong foundation for the future, and I could not be happier or prouder that it is exactly Nickyl who will continue to lead Epassi’s remarkable growth journey. He brings impressive experience, strategic vision, and inspiring leadership to take Epassi through its next phase of growth.”

Nickyl Raithatha, incoming CEO of Epassi, said: “I'm thrilled to be joining Epassi at such an exciting moment in its journey. The progress the team has made in building a multi-product, multi-geography business is remarkable and reflects both the strength of the people here and the ambition that drives the company forward. I’m looking forward to working with Pekka and everyone at Epassi as we accelerate our growth and build the leading digital employee benefits platform in Europe.”

Notes to Editors

About Epassi

Founded in Helsinki in 2007, Epassi is a pioneering employee benefits technology provider and leading global multi-benefits platform with a strong presence in the Nordics, Germany, the Netherlands, Italy, the UK, Ireland, Spain, Portugal, and France. Epassi’s innovative, unique and scalable solution combines all benefits into one mobile app-centric, user-friendly digital service, providing a digital marketplace for employee benefits.

Epassi Group serves more than 50,000 employers and their over 30 million employees, with a partner network of more than 100,000 service providers. Epassi is a leading fintech company, recognized by the Financial Times as one of the fastest growing companies in Europe in 2022, 2023, 2024 and 2025, and ranked 32nd on Europe’s Long-Term Growth Champions 2025 list. Epassi Group is backed by TA Associates and Warburg Pincus.

Epassi – Boosting everyday well-being.

www.epassi.com

About Nickyl Raithatha

Nickyl Raithatha is an experienced technology leader with a strong track record of scaling digital-first businesses across B2C, B2B, and marketplace ecosystems. He most recently served as Chief Executive Officer of Moonpig Group, where he led the company through a period of substantial growth and expansion into new markets. During his tenure, Moonpig quadrupled revenues and grew EBITDA fivefold, evolving from a UK-focused business into an international platform operating across five countries. In 2021, Nickyl led the successful £1.4bn IPO of Moonpig on the London Stock Exchange.

Before Moonpig, Nickyl founded and led Finery, an online British womenswear brand, and previously served as a Chief Executive Officer Ecommerce at Rocket Internet, supporting the growth of internet and technology businesses globally. Earlier in his career, he held VP roles in financial services at Goldman Sachs and Arrowgrass Capital Partners.

Nickyl holds an MBA from Harvard Business School and a bachelor’s degree in Economics from the University of Cambridge.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251126015983/en/

Contacts

Pekka Rantala
Group CEO
pekka.rantala@epassi.com

Alice Gibb
Director – Europe Communications, Warburg Pincus
Alice.gibb@warburgpincus.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye